论文部分内容阅读
目的:研究并对比治疗肺结核患者时使用利福喷丁与利福平的治疗效果。方法:收集肺结核患者共103例,根据患者入院日期的单双号数分为50例对照组和53例观察组,对照组患者使用利福平进行治疗,观察组使用利福喷丁进行治疗,将两组患者的明显吸收率、痰菌转阴率、空洞闭合率以及不良反应发生率进行观察和对比。结果:观察组患者的明显吸收率明显高于对照组,观察组患者的痰菌转阴率显著高于对照组,观察组患者的空洞闭合率显著高于对照组,观察组的不良反应发生率显著低于对照组(P均<0.05)。结论:在肺结核患者的治疗过程中使用利福喷丁,能够保证治疗效果,且患者的不良反应发生率低,更加安全可靠,值得推广应用。
OBJECTIVE: To study and compare the therapeutic effects of rifapentine and rifampicin in the treatment of patients with pulmonary tuberculosis. Methods: A total of 103 patients with pulmonary tuberculosis were collected. According to the single and double numbers of admission date, the patients were divided into 50 control groups and 53 observation groups. The control group was treated with rifampicin. The observation group was treated with rifapentine. The two groups of patients with significant absorption rate, sputum negative rate, void closure rate and the incidence of adverse reactions were observed and compared. Results: The apparent absorption rate of patients in the observation group was significantly higher than that of the control group. The negative rate of sputum bacteria in the observation group was significantly higher than that in the control group. The void closure rate in the observation group was significantly higher than that in the control group. The incidence of adverse reactions in the observation group Significantly lower than the control group (all P <0.05). Conclusion: The use of rifapentin in the treatment of patients with tuberculosis can ensure the therapeutic effect, and the incidence of adverse reactions in patients is low, more safe and reliable, which is worth popularizing and applying.